Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Obesity
Interventions: 4% Lidocaine, Saline; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Critical Illness, Sepsis, Multiple Organ Failure
Interventions: Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo; Other
Lead sponsor: Daren K. Heyland; Other
Eligibility: 18 Years and older
Enrollment: 1,223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 5
States / cities: Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more

Conditions: Acute Respiratory Distress Syndrome, Infections
Interventions: Rhu-pGSN, normal saline; Drug
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more

Conditions: Pneumococcal Disease
Interventions: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Uterine Atony With Hemorrhage
Interventions: Methylergonovine, Normal Saline (placebo); Drug
Lead sponsor: Cynthia Wong; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy Participants
Interventions: CDX-622, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cystic Fibrosis
Interventions: Gallium nitrate, Normal Saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more

Conditions: Cough, Nerve Block
Interventions: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pain
Interventions: J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose; Device · Other · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 6 Months to 6 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pain, Procedural, Minor Laceration, Abscess
Interventions: Ketamine, Saline; Drug · Other
Lead sponsor: Loyola University; Other
Eligibility: 7 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Wounds and Injuries, Respiratory Failure, Pneumonia, Ventilator-Associated
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Nicholas M Mohr; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Labor
Interventions: Ephedrine, Normal Saline Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemopneumothorax, Pneumothorax
Interventions: Ancef or Clindamycin, Placebo; Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 16 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Mixed Dyslipidemia
Interventions: ARO-ANG3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more

Conditions: Stroke, Ischemic
Interventions: RNS60, Placebo; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 3 more

Conditions: Traumatic Brain Injury
Interventions: 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more

Conditions: Bronchiolitis
Interventions: Furosemide, Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: Up to 48 Months
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Pitt Hopkins Syndrome
Interventions: MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 5 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Plasmodium Falciparum Malaria
Interventions: Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Duration of Interscalene Block
Interventions: ropivacaine plus dexamethasone anesthetic, ropivacaine plus saline plus dexamethasone anesthetic; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mucositis, Head and Neck Cancer
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

A Phase I Study of CDX-622

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough

The Use of Jet Injection Lidocaine for Blood Draws in Young Children

Ketamine as a Supplement to Local Anesthesia for Minor Procedures

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Prehospital Ventilator-Associated Pneumonia Prevention Trial

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer